Related Experiment Video
Updated: Feb 7, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
EngineeredHouttuynia cordata-derived exosome-like nanoparticles as a dual-targeting platform for eradicating
Zhi Gong1, Ruixue Zhang1, Gongming Shi2
1School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, Chongqing 401331, China.
Abstract:
Intracellular infections caused by methicillin-resistant Staphylococcus aureus (MRSA) present a significant therapeutic challenge due to the limited access of conventional antibiotics to bacterial reservoirs within macrophages. To address this, we developed a dual-targeting delivery system using Houttuynia cordata-derived exosome-like nanoparticles (HELNs) functionalized with mannose and vancomycin for rifampicin (Rif) encapsulation (Rif@HELNs-MV). The engineered nanoparticles were designed to sequentially target macrophages through mannose receptor-mediated endocytosis and subsequently bind to intracellular MRSA via vancomycin-peptidoglycan interactions. Systematic characterization revealed that Rif@HELNs-MV maintained structural integrity with a spherical morphology, high Rif loading capacity (18.3 ± 2.1 %). Cellular assays demonstrated enhanced uptake and precise targeting to intracellular MRSA. The formulation showed superior antibacterial efficacy in murine models of peritonitis and muscle infection, significantly reducing bacterial loads while exhibiting excellent biocompatibility. This dual-targeting strategy represents a promising approach for treating persistent intracellular infections by overcoming the physiological barriers that limit conventional antibiotic therapies.
Insights
A novel dual-targeting nanoparticle system effectively delivers rifampicin to combat intracellular methicillin-resistant Staphylococcus aureus (MRSA) infections. This approach overcomes antibiotic access barriers, showing promise for treating persistent bacterial reservoirs.
Area of Science:
- Nanomedicine
- Infectious Diseases
- Microbiology
Background:
- Intracellular infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are difficult to treat due to limited antibiotic penetration into macrophage reservoirs.
- Conventional therapies struggle to reach bacteria residing within host cells, leading to persistent infections.
Purpose of the Study:
- To develop and evaluate a dual-targeting nanoparticle system for enhanced delivery of rifampicin to intracellular MRSA.
- To overcome physiological barriers limiting conventional antibiotic efficacy against intracellular pathogens.
Main Methods:
- Engineered Houttuynia cordata-derived exosome-like nanoparticles (HELNs) encapsulating rifampicin (Rif) and functionalized with mannose and vancomycin (Rif@HELNs-MV).
- Investigated mannose receptor-mediated endocytosis for macrophage targeting and vancomycin-mediated binding to intracellular MRSA.
- Characterized nanoparticle morphology, Rif loading capacity, cellular uptake, and antibacterial efficacy in murine infection models.
Main Results:
- Rif@HELNs-MV nanoparticles exhibited spherical morphology and high rifampicin loading capacity (18.3 ± 2.1%).
- Demonstrated enhanced cellular uptake and precise targeting of intracellular MRSA.
- Showed superior antibacterial efficacy in murine peritonitis and muscle infection models, significantly reducing bacterial loads with good biocompatibility.
Conclusions:
- The dual-targeting strategy using Rif@HELNs-MV effectively delivers antibiotics to intracellular MRSA reservoirs.
- This nanomedicine approach shows significant potential for treating persistent intracellular bacterial infections by overcoming conventional therapeutic limitations.
Related Concept Videos
Intracellular Signaling Cascades
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
What is Genetic Engineering?
Resistivity
Resistance
Equivalent Resistance

